In the latest instalment of Bell Direct’s From the Helm series, Jess speaks with Immutep’s CEO Marc Voigt.
What areas in healthcare do Immutep (ASX:IMM) compete in? Marc explains Immutep’s hand in immuno-oncology and immunotherapy, and how their range of products help save lives. How is the Immutep metastatic breast cancer treatment potentially going to shape the world of immuno-oncology treatments in breast cancer? What would the success of these clinical trials mean for business?
Plus, a quick word on COVID-19 and its impacts on the business.